Trial Profile

A first in human phase 1 clinical study of ET-D5 for sacoma and solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ET D5 (Primary)
Indications Sarcoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

10 Oct 2019 New trial record
24 Sep 2019 According to an Ecrins Therapeutics media release, the trial is anticipated to start in 2020.
24 Sep 2019 According to an Ecrins Therapeutics media release, the company submitted to the FDA a pre-IND package, the FDA agreed completed GLP nonclinical studies. The FDA also agreed to the proposed clinical trial design, endpoints and study procedures.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com